Your browser doesn't support javascript.
loading
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels, S; Pugliano, L; Marguet, S; Grun, D; Barinoff, J; Cameron, D; Cobleigh, M; Di Leo, A; Johnston, S; Gasparini, G; Kaufman, B; Marty, M; Nekljudova, V; Paluch-Shimon, S; Penault-Llorca, F; Slamon, D; Vogel, C; von Minckwitz, G; Buyse, M; Piccart, M.
Affiliation
  • Michiels S; Unit of Biostatistics and Epidemiology, Gustave Roussy, Villejuif; University Paris-Sud, University Paris-Saclay, UVSQ, CESP, INSERM, Villejuif; Plateform Ligue nationale contre le cancer for meta-analyses in oncology, Gustave Roussy, Villejuif, France; Institut Jules Bordet, Université Libre de Bru
  • Pugliano L; Institut Jules Bordet, Université Libre de Bruxelles, Brussels; Breast International Group (BIG), Brussels, Belgium.
  • Marguet S; Unit of Biostatistics and Epidemiology, Gustave Roussy, Villejuif.
  • Grun D; Institut Jules Bordet, Université Libre de Bruxelles, Brussels.
  • Barinoff J; Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany.
  • Cameron D; Department of Oncology, University of Edinburgh, Edinburgh, UK.
  • Cobleigh M; Rush University Medical Center, Chicago, USA.
  • Di Leo A; Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy.
  • Johnston S; Breast Unit, Royal Marsden Hospital, London, UK.
  • Gasparini G; Scientific Direction, IRCCS National Cancer Research Centre "Giovanni Paolo II,"Bari, Italy.
  • Kaufman B; The Institute of Breast Oncology, Sheba Medical Center, Tel Hashomer, Israel.
  • Marty M; Breast Cancer Diseases Unit and Department of Medical Oncology, Saint Louis Hospital, APHP, Paris, France.
  • Nekljudova V; German Breast Group, GBG ForschungsGmbH, Neu-Isenburg, Germany.
  • Paluch-Shimon S; The Institute of Breast Oncology, Sheba Medical Center, Tel Hashomer, Israel.
  • Penault-Llorca F; Department of Pathology, Centre Jean Perrin, EA 4233, University of Auvergne, Clermont-Ferrand, France.
  • Slamon D; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles.
  • Vogel C; University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, Columbia Cancer Research Network of Florida, Miami, USA.
  • von Minckwitz G; German Breast Group, GBG ForschungsGmbH, Neu-Isenburg, Germany.
  • Buyse M; IDDI, Louvain-la-Neuve, Hasselt University, Hasselt, Belgium.
  • Piccart M; Institut Jules Bordet, Université Libre de Bruxelles, Brussels; Breast International Group (BIG), Brussels, Belgium.
Ann Oncol ; 27(6): 1029-1034, 2016 06.
Article in En | MEDLINE | ID: mdl-26961151
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Receptor, ErbB-2 / Disease-Free Survival / Trastuzumab Type of study: Clinical_trials / Systematic_reviews Limits: Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Breast Neoplasms / Receptor, ErbB-2 / Disease-Free Survival / Trastuzumab Type of study: Clinical_trials / Systematic_reviews Limits: Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2016 Type: Article